Cargando…

The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study

BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ita, Michael Itak, Wang, Jiang Huai, Toulouse, André, Lim, Chris, Fanning, Noel, O’Sullivan, Michael, Nolan, Yvonne, Kaar, George Finbarr, Redmond, Henry Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913523/
https://www.ncbi.nlm.nih.gov/pubmed/34643804
http://dx.doi.org/10.1007/s00701-021-05014-8
_version_ 1784667460305158144
author Ita, Michael Itak
Wang, Jiang Huai
Toulouse, André
Lim, Chris
Fanning, Noel
O’Sullivan, Michael
Nolan, Yvonne
Kaar, George Finbarr
Redmond, Henry Paul
author_facet Ita, Michael Itak
Wang, Jiang Huai
Toulouse, André
Lim, Chris
Fanning, Noel
O’Sullivan, Michael
Nolan, Yvonne
Kaar, George Finbarr
Redmond, Henry Paul
author_sort Ita, Michael Itak
collection PubMed
description BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exist in the plasma transcriptomic profile of glioma patients relative to differences in their tumour characteristics, and also whether any observed differences were representative of synchronously obtained glioma samples and TCGA glioma-derived RNA. METHODS: Blood samples were collected from twenty glioma patients prior to tumour resection. Plasma ccfmRNAs and glioma-derived RNA were extracted and profiled. RESULTS: BCL2L1, GZMB, HLA-A, IRF1, MYD88, TLR2, and TP53 genes were significantly over-expressed in glioma patients (p < 0.001, versus control). GZMB and HLA-A genes were significantly over-expressed in high-grade glioma patients (p < 0.001, versus low-grade glioma patients). Moreover, the fold change of the BCL2L1 gene was observed to be higher in patients with high-grade glioma (p = 0.022, versus low-grade glioma patients). There was positive correlation between the magnitude of fold change of differentially expressed genes in plasma- and glioma-derived RNA (Spearman r = 0.6344, n = 14, p = 0.017), and with the mean FPKM in TCGA glioma-derived RNA samples (Spearman r = 0.4614, n = 19, p < 0.05). There was positive correlation between glioma radiographic tumour burden and the magnitude of fold change of the CSF3 gene (r = 0.9813, n = 20, p < 0.001). CONCLUSION: We identified significant differential expression of genes involved in cancer inflammation and immunity crosstalk among patients with different glioma grades, and there was positive correlation between their transcriptomic profile in plasma and tumour samples, and with TCGA glioma-derived RNA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00701-021-05014-8.
format Online
Article
Text
id pubmed-8913523
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-89135232022-03-15 The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study Ita, Michael Itak Wang, Jiang Huai Toulouse, André Lim, Chris Fanning, Noel O’Sullivan, Michael Nolan, Yvonne Kaar, George Finbarr Redmond, Henry Paul Acta Neurochir (Wien) Original Article - Brain Tumors BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exist in the plasma transcriptomic profile of glioma patients relative to differences in their tumour characteristics, and also whether any observed differences were representative of synchronously obtained glioma samples and TCGA glioma-derived RNA. METHODS: Blood samples were collected from twenty glioma patients prior to tumour resection. Plasma ccfmRNAs and glioma-derived RNA were extracted and profiled. RESULTS: BCL2L1, GZMB, HLA-A, IRF1, MYD88, TLR2, and TP53 genes were significantly over-expressed in glioma patients (p < 0.001, versus control). GZMB and HLA-A genes were significantly over-expressed in high-grade glioma patients (p < 0.001, versus low-grade glioma patients). Moreover, the fold change of the BCL2L1 gene was observed to be higher in patients with high-grade glioma (p = 0.022, versus low-grade glioma patients). There was positive correlation between the magnitude of fold change of differentially expressed genes in plasma- and glioma-derived RNA (Spearman r = 0.6344, n = 14, p = 0.017), and with the mean FPKM in TCGA glioma-derived RNA samples (Spearman r = 0.4614, n = 19, p < 0.05). There was positive correlation between glioma radiographic tumour burden and the magnitude of fold change of the CSF3 gene (r = 0.9813, n = 20, p < 0.001). CONCLUSION: We identified significant differential expression of genes involved in cancer inflammation and immunity crosstalk among patients with different glioma grades, and there was positive correlation between their transcriptomic profile in plasma and tumour samples, and with TCGA glioma-derived RNA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00701-021-05014-8. Springer Vienna 2021-10-13 2022 /pmc/articles/PMC8913523/ /pubmed/34643804 http://dx.doi.org/10.1007/s00701-021-05014-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article - Brain Tumors
Ita, Michael Itak
Wang, Jiang Huai
Toulouse, André
Lim, Chris
Fanning, Noel
O’Sullivan, Michael
Nolan, Yvonne
Kaar, George Finbarr
Redmond, Henry Paul
The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
title The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
title_full The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
title_fullStr The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
title_full_unstemmed The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
title_short The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study
title_sort utility of plasma circulating cell-free messenger rna as a biomarker of glioma: a pilot study
topic Original Article - Brain Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913523/
https://www.ncbi.nlm.nih.gov/pubmed/34643804
http://dx.doi.org/10.1007/s00701-021-05014-8
work_keys_str_mv AT itamichaelitak theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT wangjianghuai theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT toulouseandre theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT limchris theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT fanningnoel theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT osullivanmichael theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT nolanyvonne theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT kaargeorgefinbarr theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT redmondhenrypaul theutilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT itamichaelitak utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT wangjianghuai utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT toulouseandre utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT limchris utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT fanningnoel utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT osullivanmichael utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT nolanyvonne utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT kaargeorgefinbarr utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy
AT redmondhenrypaul utilityofplasmacirculatingcellfreemessengerrnaasabiomarkerofgliomaapilotstudy